FOR IMMEDIATE RELEASE
MESA, Ariz. — August 11, 2023
Just published in the Journal of Clinical and Translational Research, The Marchand Institute’s new study on 20% intravenous fat emulsion therapy (also known as IntralipidTM), shows the effect of this medication on patients who suffer from recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF) who are seeking to conceive via invitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The article is available online complete free at the US Government’s Pubmed website as well as Semantic ScholarTM.
About the Marchand Institute for Minimally Invasive Surgery
The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised using the Cochrane RoB 2 tool. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS.
Media Contact
Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com | (480) 999-0905
Interview requests, expert commentary topics, boilerplate and high-resolution images: Newsroom & Press Kit. Complete publication record with DOIs and PMIDs: Publications database. Methodology: How we run a review.
###